James M Angelastro

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/292798/james-m-angelastro-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| 35 | 1,610 | 19 | 36 |
|-------------|----------------------|---------|---------|
| papers | citations | h-index | g-index |
| 36 | 1,752 ext. citations | 6 | 4.34 |
| ext. papers | | avg, IF | L-index |

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 35 | Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents. <i>Cancers</i> , 2021 , 13, | 6.6 | 3 |
| 34 | Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 133, 111058 | 7.5 | 6 |
| 33 | PRMT1 promotes neuroblastoma cell survival through ATF5. <i>Oncogenesis</i> , 2020 , 9, 50 | 6.6 | 10 |
| 32 | Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD. <i>Molecular Cancer Research</i> , 2020 , 18, 216-228 | 6.6 | 13 |
| 31 | Cetylpyridinium chloride is a potent AMP-activated kinase (AMPK) inducer and has therapeutic potential in cancer. <i>Mitochondrion</i> , 2020 , 50, 19-24 | 4.9 | 4 |
| 30 | Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells. <i>Pharmaceuticals</i> , 2020 , 13, | 5.2 | 3 |
| 29 | Dominant-negative ATF5 rapidly depletes survivin in tumor cells. <i>Cell Death and Disease</i> , 2019 , 10, 709 | 9.8 | 6 |
| 28 | Expression and targeting of transcription factor ATF5 in dog gliomas. <i>Veterinary and Comparative Oncology</i> , 2018 , 16, 102-107 | 2.5 | 9 |
| 27 | Targeting ATF5 in Cancer. <i>Trends in Cancer</i> , 2017 , 3, 471-474 | 12.5 | 17 |
| 26 | The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer. <i>Oncotarget</i> , 2017 , 8, 84595-84609 | 3.3 | 23 |
| 25 | Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide. <i>Oncotarget</i> , 2016 , 7, 12718-30 | 3.3 | 18 |
| 24 | A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. <i>Clinical Cancer Research</i> , 2016 , 22, 4698-711 | 12.9 | 52 |
| 23 | Reciprocal actions of ATF5 and Shh in proliferation of cerebellar granule neuron progenitor cells. <i>Developmental Neurobiology</i> , 2012 , 72, 789-804 | 3.2 | 8 |
| 22 | Premutation CGG-repeat expansion of the Fmr1 gene impairs mouse neocortical development. <i>Human Molecular Genetics</i> , 2011 , 20, 64-79 | 5.6 | 65 |
| 21 | Overexpression of CD133 promotes drug resistance in C6 glioma cells. <i>Molecular Cancer Research</i> , 2010 , 8, 1105-15 | 6.6 | 62 |
| 20 | Identification of a novel DNA binding site and a transcriptional target for activating transcription factor 5 in c6 glioma and mcf-7 breast cancer cells. <i>Molecular Cancer Research</i> , 2009 , 7, 933-43 | 6.6 | 32 |
| 19 | The transcription factor ATF5: role in neurodevelopment and neural tumors. <i>Journal of Neurochemistry</i> , 2009 , 108, 11-22 | 6 | 60 |

(1990-2007)

| 18 | The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. <i>International Journal of Cancer</i> , 2007 , 120, 1883-90 | 7.5 | 67 |
|----|--|-----|-----|
| 17 | Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007 , 85, 149-57 | 4.8 | 22 |
| 16 | Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. <i>Oncogene</i> , 2006 , 25, 907-16 | 9.2 | 70 |
| 15 | Analysis of gene expression changes in a cellular model of Parkinson disease. <i>Neurobiology of Disease</i> , 2005 , 18, 54-74 | 7.5 | 74 |
| 14 | ATF5 regulates the proliferation and differentiation of oligodendrocytes. <i>Molecular and Cellular Neurosciences</i> , 2005 , 29, 372-80 | 4.8 | 53 |
| 13 | You cana go home again: transcriptionally driven alteration of cell signaling by NGF. <i>Neurochemical Research</i> , 2005 , 30, 1347-52 | 4.6 | 18 |
| 12 | Downregulation of activating transcription factor 5 is required for differentiation of neural progenitor cells into astrocytes. <i>Journal of Neuroscience</i> , 2005 , 25, 3889-99 | 6.6 | 69 |
| 11 | Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons. Journal of Neuroscience, 2003, 23, 4590-600 | 6.6 | 106 |
| 10 | The basic region and leucine zipper transcription factor MafK is a new nerve growth factor-responsive immediate early gene that regulates neurite outgrowth. <i>Journal of Neuroscience</i> , 2002 , 22, 8971-80 | 6.6 | 39 |
| 9 | Nerve growth factor selectively regulates expression of transcripts encoding ribosomal proteins. <i>BMC Neuroscience</i> , 2002 , 3, 3 | 3.2 | 29 |
| 8 | Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinsona disease. <i>Journal of Neuroscience</i> , 2002 , 22, 10690-8 | 6.6 | 457 |
| 7 | Characterization of a novel isoform of caspase-9 that inhibits apoptosis. <i>Journal of Biological Chemistry</i> , 2001 , 276, 12190-200 | 5.4 | 34 |
| 6 | Death in the balance: alternative participation of the caspase-2 and -9 pathways in neuronal death induced by nerve growth factor deprivation. <i>Journal of Neuroscience</i> , 2001 , 21, 5007-16 | 6.6 | 126 |
| 5 | Peripherin is tyrosine-phosphorylated at its carboxyl-terminal tyrosine. <i>Journal of Neurochemistry</i> , 1998 , 70, 540-9 | 6 | 19 |
| 4 | Tyrosine phosphorylation of extracellular signal-regulated protein kinase 4 in response to growth factors. <i>Journal of Neurochemistry</i> , 1996 , 66, 1191-7 | 6 | 18 |
| 3 | Adenine and guanine nucleotide content of Triton-extracted cytoskeletal fractions of nonmuscle cells. <i>Analytical Biochemistry</i> , 1992 , 204, 47-52 | 3.1 | 4 |
| 2 | Evidence against impaired brain microtubule protein polymerization at high glucose concentrations or during diabetes mellitus. <i>Journal of Neurochemistry</i> , 1991 , 56, 2087-93 | 6 | 6 |
| 1 | Apparently irreversible GTP hydrolysis attends tubulin self-assembly. <i>FEBS Journal</i> , 1990 , 191, 507-11 | | 8 |